Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 63701 record(s)

Req # A-2023-000915

Adverse Drug Reactions (ADRs). Report numbers: E2B_06142348, E2B_06142824.

Organization: Health Canada

22 page(s)
March 2024

Req # A-2023-000917

Adverse Drug Reaction (ADR). Report number: E2B_06425030.

Organization: Health Canada

146 page(s)
March 2024

Req # A-2023-000924

Adverse Drug Reaction (ADR). Report number: E2B_06027460.

Organization: Health Canada

657 page(s)
March 2024

Req # A-2023-001015

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107383-601.

Organization: Health Canada

21 page(s)
March 2024

Req # A-2023-001026

Adverse Drug Reactions (ADRs) for DEXILANT. Report numbers: 001058652, 001059169, E2B_06550206. ADRs for ENTYVIO. Report numbers: E2B_06551013, 001054666, E2B_06540809, E2B_06571640, 001054676. ADRs for MESALAMINE. Report numbers: E2B_06525848, E2B_06573163.

Organization: Health Canada

111 page(s)
March 2024

Req # A-2023-001031

Adverse Drug Reactions (ADRs) for ONDANSETRON. Report numbers: 001051602, E2B_06544200, E2B_06544246, E2B_06549302, E2B_06549717, E2B_06550996, E2B_06559699, E2B_06566386. ADRs for LANSOPRAZOLE. Report numbers: E2B_06560926, 001057449.

Organization: Health Canada

604 page(s)
March 2024

Req # A-2023-001035

Adverse Drug Reactions (ADRs). Report numbers: E2B_06586522, E2B_06577728, 001058691, 001058257, E2B_06425916, E2B_05046859.

Organization: Health Canada

101 page(s)
March 2024

Req # A-2023-001042

Adverse Drug Reactions (ADRs) for EMEND. Report numbers: 000921572, 000926951, 000929133, 000930002. ADRs for EMEND IV. Report numbers: E2B_03477895, E2B_02336796, 000725466, 000732475.

Organization: Health Canada

251 page(s)
March 2024

Req # A-2023-001077

Adverse Drug Reactions (ADRs). Report numbers: E2B_06553666, 001060638, 001062401, E2B_00146713, 001057489, 01051366, E2B_06566392, 001051594, 001051599, 01050689.

Organization: Health Canada

399 page(s)
March 2024

Req # A-2023-001094

Adverse Drug Reactions (ADRs) for EMEND IV. Report numbers: E2B_02534490, E2B_00236901, 000948750. ADR for INTEGRILIN. Report number: E2B_03438497. ADRs for INTRON A. Report numbers: 000928459, 000945380. ADRs for INVANZ. Report numbers: E2B_04425235, E2B_02446830, E2B_04425447, E2B_04430322.

Organization: Health Canada

986 page(s)
March 2024
Date modified: